Needham & Company Raises Price Target on Rogers (ROG) to $75 Following Solid 3Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Rogers (ROG) Tops Q3 EPS by 20c
November 2, 2016 5:45 PM EDTRogers (NYSE: ROG) reported Q3 EPS of $0.88, $0.20 better than the analyst estimate of $0.68. Revenue for the quarter came in at $165.3 million versus the consensus estimate of $154.02 million.
For earnings history and earnings-related data on Rogers (ROG) click here.
... MoreGenentech (RHHBY) Plans Presentation of New Actemra, Rituxan Data at 2016 ACR/ARHP Annual Meeting
November 2, 2016 6:27 AM EDTGenentech, a member of the Roche Group (OTC: RHHBY) announced that new data from Actemra (tocilizumab) and Rituxan (rituximab) will be presented during the 2016 American College of Rheumatology (ACR) and Association for Rheumatology Health Professionals (ARHP) Annual Meeting, November 11-16, Washington, D.C. These data add to the significant body of evidence for Actemra and Rituxan in RA and other serious immune-mediated conditions including GCA, systemic sclerosis (SSc), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).
Advances in our scientific understanding behind immune pathways are guiding the development of potential new treatments for severe... More
